UNSPSC 51351601: 16-epiestriol

This classification denotes a steroidal estrogen with the molecular formula C18H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XZ32LI44K, chemically known as 3,16beta,17beta-trihydroxy-1,3,5(10)-estratriene but generally known as 16-epiestriol, which bears US NIH Compound Identifier 3269. European Medicines Agency schedules Epiestriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06565MIG.

The term EPIESTRIOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). SMILES: CC12CCC3C(C1CC(C2O)O)CCC4=C3C=CC(=C4)O.

UNSPSC 51351601 Epiestriol, a Commodity code, encompasses pharmaceutical products supplied through state and local cooperative purchasing vehicles and healthcare facilities. Recent activity shows state and local governments procuring generic pharmaceuticals and over-the-counter products through established multistate cooperative purchasing alliances rather than individual agency solicitations. The work involves manufacturers and distributors meeting cGMP and Drug Supply Chain Security Act compliance requirements, securing wholesale distribution relationships, and pricing products competitively across multiple strength and packaging configurations identified by the purchasing body.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities, including Oregon, with proposals due March 26, 2026. Awarded vendors must maintain relationships with three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures. Evaluation emphasizes price competitiveness (75 percent), compliance with administrative data-format requirements (5 percent), EDI capability (5 percent), fixed pricing for the contract term (10 percent), and agreement to a 3 percent administrative fee (5 percent). Products must be available in the marketplace by May 15, 2026, with the contract term two years for new responders and optional extensions at MMCAP's discretion, and the resulting agreements effective July 1, 2026. No specific dollar values or set-aside designations are disclosed in available documentation.